Lance Lemon, MD
Ophthalmology · Lansing, MINPI 1669490702
Payments from drug & device makers
Across 256 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$955
- Bausch & Lomb Americas Inc.$534
- Mallinckrodt Hospital Products Inc.$521
- Kala Pharmaceuticals, Inc.$345
- Novartis$331
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,59598%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 62 | $1,488 |
| AbbVie(2 entities) | 43 | $955 |
| Bausch & Lomb Americas Inc. | 25 | $534 |
| Mallinckrodt Hospital Products Inc. | 23 | $521 |
| Kala Pharmaceuticals, Inc. | 16 | $345 |
| Novartis | 16 | $331 |
| ANI Pharmaceuticals, Inc. | 8 | $197 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $162 |
| Shire North American Group Inc | 6 | $152 |
| Oyster Point Pharma, Inc. | 3 | $129 |
| Aerie Pharmaceuticals, Inc. | 7 | $120 |
| Tarsus Pharmaceuticals, Inc. | 4 | $115 |
| NEW World Medical,inc. | 6 | $100 |
| Johnson & Johnson | 3 | $99 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $85 |
| Rayner Intraocular Lenses Limited | 3 | $65 |
| Glaukos Corporation | 4 | $62 |
| Dompe US, Inc. | 2 | $38 |
| Ivantis, Inc | 2 | $37 |
| Sight Sciences, Inc. | 2 | $34 |
| Omeros Corporation | 2 | $30 |
| Sun Pharmaceutical Industries Inc. | 2 | $24 |
| Rxsight Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,695 in reported general payments places this provider in the 85th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 321 | $156,775 |
| RestasisCyclosporine | 72 | $105,449 |
| VyzultaLatanoprostene Bunod | 205 | $79,593 |
| Cyclosporine | 106 | $68,329 |
| RhopressaNetarsudil Mesylate | 142 | $54,625 |
| XiidraLifitegrast | 39 | $54,455 |
| Bromfenac Sodium | 300 | $46,289 |
| Prednisolone Acetate | 951 | $42,267 |
| Travoprost | 261 | $41,805 |
| RocklatanNetarsudil Mesylat/Latanoprost | 83 | $41,085 |
| Brimonidine Tartrate | 288 | $38,780 |
| Bimatoprost | 265 | $27,976 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 120 | $26,383 |
| Brinzolamide | 129 | $21,486 |
| Latanoprost | 1,007 | $20,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $955 | $291,576487 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $534 | $134,048244 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $120 | $95,710225 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Loteprednol Etabonate, Prolensa | $162 | $37,534191 claims |
| AlconSimbrinza | $1,488 | $26,383120 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $129 | $16,97516 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $345 | $15,96351 claims |
| NovartisIlevro | $331 | $3,95011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Lansing
- Mahdi BashaFraser$2.2M
- Thomas WubbenAnn Arbor$1.2M
- Manjool ShahAnn Arbor$745K
- Scott WesthouseGrand Rapids$525K
- Gregory KatzYpsilanti$495K
- Cagri BesirliAnn Arbor$441K
- David BrownSaint Joseph$432K
- Vinay AakaluAnn Arbor$429K
- Timothy PageBirmingham$324K
- David CookeSaint Joseph$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.